Tumor infiltrating lymphocytes in uveal melanoma: A link with clinical behavior?

International Journal of Immunopathology and Pharmacology

Volumn 19, Issue 1, 2006, Pages 171-179

  Staibano, S ^a   Mascolo, M ^a   Tranfa, F ^a   Salvatore, G ^a   Mignogna, C ^a   Bufo, P ^b   Nugnes, L ^a   Bonavolonta G ^a   De Rosa, G ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

Author keywords

Fas linked apoptosis; Prognosis; TCR chain; TIL; Uveal melanoma

Indexed keywords

APOPTOSIS INDUCING FACTOR; FAS ANTIGEN; FAS LIGAND; T LYMPHOCYTE RECEPTOR;

ADULT; AGED; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DISEASE COURSE; ENUCLEATION; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; UVEA MELANOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD95; FAS LIGAND PROTEIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOCYTES; MALE; MELANOMA; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PHENOTYPE; RECEPTORS, ANTIGEN, T-CELL; TUMOR NECROSIS FACTORS; UVEAL NEOPLASMS;

EID: 33646248383     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Singh A.D. and A. Topham. 2003. Incidence of uveal melanoma in the United States: 1973-97. Ophthalmology 110:956.
2. Jemal A, A. Thomas, T. Murray and M. Thun. 2002. Cancer statistics, 2002. CA Cancer J. Clin. 52:23.
3. Repp A.C., E.S. Mayhew, S. Apte and J.Y. Niederkorn. 2000. Human uveal melanoma cells produce macrophage migration inhibitory factor to prevent lysis by NK cells. J. Immunol. 165:710.
4. Carlring J., M. Shaif-Muthana, K. Sisley, I.G. Rennie and A.K. Murray. 2003. Apoptotic cell death in conjunction with CD80 costimulation confers uveal melanoma cells with the ability to induce immune responses. Immunology. 109:41.
5. Singh A.D., C.L. Shields and J.A. Shields. 2001. Prognostic factors in uveal melanoma. Melanoma Res. 11:255.
6. Zaldivar R.A., T.M. Aaberg, P. Sternberg Jr., R. Waldron and H.E. Grossniklaus. 2003. Clinicopathologic findings in choroidal melanomas after failed transpupillary thermotherapy. Am. J. Ophthalmol. 135:657.
7. Puusaari I., J. Heikkonen, P. Summanen, A. Tarkkanen and T. Kivela. 2003. Iodine brachytherapy as an alternative to enucleation for large uveal melanomas. Ophthalmology 110: 2223.
8. Bell D.J. and M.W. Wilson 2004. Choroidal melanoma: Natural history and management options. Cancer Control 11:296.
9. Kujala E., T. Makime and T. Kivela. 2003. Very long-term prognosis of patients with malignant uveal melanoma. Invest. Ophthalmol. Vis. Sci. 44:4651.
10. Paul E.V., B.L. Parnell and M. Fraker. 1962. Prognosis of malignant melanomas of the choroids and ciliary body. Int. Ophthalmol. Clin. 2:387.
11. Affeldt J.C., D.S. Minckler, S.P. Azen and L. Yeh. 1980. Prognosis in uveal melanoma with extrascleral extension. Arc. Ophthalmol. 98:1975.
12. Anastassiou G., S.E. Coupland, A. Stang, R. Boeloeni, H. Schilling and N. Bornfeld. 2001. Expression of Fas and Fas ligand in uveal melanoma: biological implication and prognostic value. J. Pathol. 194:466.
13. Niederkorn J.Y. 1997. Immunoregulation of intraocular tumours. Eye 11:249.
14. Apte R.S., E. Mayhew and J.Y. Niederkorn. 1997. Local inhibition of natural killer cell activity promotes the progressive growth of intraocular tumors. Invest. Ophthalmol. Vis. Sci. 38:1277.
15. De Waard-Siebinga I., C.G.J.M. Hilders, B.E. Hansen, J.L. Van Delft and M.J. Jager. 1996. HLA expression and tumor-infiltrating immune cells in uveal melanoma. Graefe's Arch. Clin. Exp. Ophthalmol. 234:34.
16. Niederkorn J.Y. and S. Wang. 2005. Immunology of intraocular tumors. Ocular Immunol. Inflamm. 13:105.
17. Lai P., H. Rabinovich, P.A. Crowley-Nowick, M.C. Bell, G. Mantovani and T.L. Whiteside. 1996. Alterations in expression and in function of signal-trasucing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma. Clin. Cancer Res. 2:161.
18. Irving B. and A. Weiss. 1991. The cytoplasmatic domain of the T cell receptor ζ chain is sufficient to couple to receptor associated signal tasduction pathway. Cell 64:891.
19. Matsuda M., M. Petersson, R. Lenkei, J.L. Taupi, I. Magnusson, H. Mellstedt, P. Anderson and R. Kiessling. 1995. Alterations in the signal-transducing molecules of T-cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease. Int. J. Cancer 61:765.
20. Kono K., M.E. Ressing, R.M.P. Brandt, C.J.M. Melief, R.K. Potkul, B. Andersson, M. Petersson, W.M. Kast and R. Kiessling. 1996. Decreased expression of signal-traucing ζ chain in peripheral T cells and natural killer cells in patients with cervical cancer. Clin. Cancer Res. 2:1985.
21. Ishigami S., S. Natsugoe, K. Tokuda, A. Nakajo, H. Higashi, H. Iwashige, H. Aridome, S. Hokita and T. Aikou. 2002. CD3-ζ chain expression of intratumoral lymphocytes is closely related to survival in gastric carcinoma patients. Cancer 94:1437.
22. Zea A.M., C.D. Brendan, D.L. Longo, W.G. Alvord, S.L. Strobl, H. Mizoguchi, S.P. Creekmore, J.J. O'Shea, G.C. Poers, J. Urba and A.C. Ochoa. 1995. Alterations in T cell receptor and signal trauction molecules in melanoma patients. Clin. Cancer Res. 1:1327.
23. Dworacki G., N. Meidenbauer, I. Kuss, T.K. Hoffmann, W. Gooding, M. Lotze and T.L. Whiteside. 2001. Decreased ζ chain expression and apoptosis in CD3+ peripheral blood T lymphocythes of patients with melanoma. Clin. Cancer Res. 7(S):947.
24. De Grujil T.D., H.J. Bontkes, F. Peccatori, M.P.W. Galee, Th.J.M. Heimerhorst, R.H.M. Verheijen, J. Aarbiou, W.M. Mulder, J.M. Walboomrs, C.J. Meijer, N. Van de Vange and R. Sheper. 1999. Expression of CD3-ζ on T-cells in primary cervical carcinoma and in metastasis-positive and -negative lymph nodes. Br. J. Cancer 79:1127.
25. Mulder W.M., E. Bloemena, M.J. Stukart, et al. 1997. T cell receptor-ζ and granzyme B expression in mononuclear cell infiltrates in normal colon mucosa and colon carcinoma. Gut 40:113.
26. Reichert T.E., R. Day, E. Wagner and T.L. Whiteside. 1998. Absent or low expression of the ζ chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma. Clin. Cancer Res. 58:5344.
27. Durie F.H., A.M. Campbell, W.R. Lee and B.E. Damato. 1990. Analysis of lymphocytic infiltration in uveal melanoma. Invest. Vis. Sci. 31:2106.
28. Blom D.J., I. De Waard-Siebinga, R.S. Apte, G.P. Luyten, J.Y. Niederkorn and M.J. Jager. 1997. Effect of hyperthermia on expression of histocompatibility antigens and heat-shock protein molecules on three human ocular melanoma cell lines. Melanoma Res. 7:103.
29. Ksander B.R., D.C. Geer, P.W. Chen, M.L. Salgaller, P. Rubsamen and T.G. Murray. 1998. Uveal MM contain antigenically specific and non-specific infiltrating lymphocytes. Curr. Eye Res. 17:165.
30. Meecham W.J., D.H. Char and S. Kaleta-Michaels. 1992. Infiltrating lymphocytes and antigen expression in uveal melanoma. Ophthalmic Res. 24:20.
31. De la Cruz P.O., C.S. Specht and I.W. McLean. 1990. Lymphocytic infiltration in uveal malignant melanoma. Cancer 65:112.
32. Hsu S.M., L. Raine and H. Fanger. 1981. Use of Avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J. Histochem. Cytochem. 29:557.
33. The Collaborative Ocular Melanoma Study Group. 1998. Histopathologic characteristics of uveal melanomas in eyes enucleated from the Collaborative Ocular Melanoma Studies. COMS report no6. Am. J. Ophthalmol. 125:745.
34. McLean I.W., W.D. Foster, L.E. Zimmermann and J.W. Gamel. 1983. Modifications of Callender's classification of uveal melanoma at the Armed forces Institute of Pathology. Am. J. Ophthalmol. 96:502.
35. Jiang L.Q., M. Jorquera and J.W. Steilen. 1994. Immunologic consequences of intraocular implantation of retinal pigment epithelial allografts. Exp. Eye Res. 58:719.
36. Jiang L.Q., M. Jorquera and J.W. Steilen. 1993. Subretinal space and vitreous cavity as immunologically privileged sites for retinal allografts. Invest. Ophthalmol. Vis. Sci. 34:3347.
37. Kremer I., E. Gilad, E. Kahan, E. Derazne and R. Bar-Ishak 1991. Necrosis and lymphocytic infiltration in choroidal melanomas. Acta Ophthalmol. 69:347.
38. Ma D., H. Alizadeh, S.A. Comerford, M.J. Gething, J.F. Sambrook, R. Anand et al. 1994. Rejection of intraocular tumors from transgenic mice by tumor-infiltrating lymphocytes. Curr. Eye Res. 13:361.
39. Davidorf F.H. and J.R. Lang. 1977. Immunology and immuno-therapy of malignant uveal melanomas. In: Intraocular tumors. Peyman ed. Apple DJ, Sanders DR. New York: Appleton/Century/Crofts p. 119.
40. Whelchel J.C., S.E. Farah, I.W. McLean and M.N. Burnier. 1993. Immunohistochemistry of infiltrating lymphocytes in uveal malignant melanoma. Invest. Ophthalmol. Vis. Sci. 34:2603.
41. Apte R. and J.Y. Niederkorn. 1996. Isolation and characterization of a unique natural killer cell inhibitory factor present in the anterior chamber of the eye. J. Immunol. 156:2667.
42. Nitta T., K. Sato, K. Okumura and L. Steinman. 1991. An analysis of T-cell-receptor variable-region genes in tumor-infiltrating lymphocytes within malignant tumors. Int. J. Cancer. 49:545.
43. Rabinowich H., T.E. Reichert, Y. Kashii, B.R. Gastman, M.C. Bell and T.L. Witheside. 1998. Lymphocyte apoptosis induced by Fas-ligand-expressing ovarian carcinoma cells. J. Clin. Invest. 101:2579.
44. Gastman B., D. Johnson, T.L. Whiteside and H. Rabinovich. 1999. Caspase-mediated degradation of T cell receptor ζ chain. Cancer Res. 59:1422.
45. Somma P., L. Lo Muzio, G. Mansueto, M. Delfino, G. Fabbrocini, M. Mascolo, C. Mignogna, M. Di Benedetto, F. Carinci, A. De Lillo, L. Pastore, R. Serpico, G. De Rosa and S. Staibano. 2005. Squamous cell carcinoma of the lower lip: FAS/FASL expression, lymphocyte subtypes and outcome. Int. J. Immunopathol. Pharmacol. 18:59.
46. Griffith T.S., T. Brunner, S.M. Fletcher, D.R. Green and T.A. Ferguson. 1995. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270:1189.
47. Streilen J.W. 1993. Immune privilege as the result of local tissue barriers and immunosuppressive microenvironments. Curr. Opin. Immunol. 5:428.
48. Wenkel H and J.W Streilen. 1998. Analysis of immune deviation elicited by antigens injected into the subretinal space. Invest. Ophthalmol. Vis. Sci. 39:1823.
49. Hallermalm K., A. De Geer, R. Klessling, V. Levitsky and J. Levitskyaya. 2004. Autocrine Secretion of Fas Ligand shields tumor cells from Fas-Mediated killing by cytotoxic lymphocytes. Cancer Res. 64:6775.
50. Hahne M., D. Rimordi, M. Schroter, P. Romero, M. Schreier, L.E. French, P. Schneider, T. Bornand, A. Fontana , D. Lienard, J. Cerottini and J. Tschopp. 1996. Melanoma cell expression of Fas (Apo-1/CD45) ligand: implications for tumor immune escape. Science 274:1363.
51. lck in T-cell infiltrating human renal cell carcinoma. Cancer Res. 53:5313.
52. Nakagomi H., M. Petersson, I. Magnusson, C. Juhlin, M. Matsuda, H. Mellstedt, J.L. Taupin, E. Vivier, P. Anderson and R. Kiessling. 1993. Decreased expression of the signal-transducing ζ chains in tumor infiltrating T cells and NK cells of patients with colorectal carcinoma. Cancer Res. 53:5610
53. Rabinowich H., M. Banks, T. Reichert, T.F. Loga, G.M. Kirkwood and T.L. Whiteside. 1996. Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after IL-2 therapy. Clin. Cancer Res. 2:1263.